Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers
Status:
Terminated
Trial end date:
2009-02-12
Target enrollment:
Participant gender:
Summary
This is a Phase III, multicenter, open-label extension, single-group study in male and female
outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed AVA105640. All
subjects will receive rosiglitazone extended-release (RSG XR) 4mg once daily for the first 4
weeks of the study followed by 8mg RSG XR. Subject participation will last until one of 5
conditions applies. After a 52-week open-label treatment phase, subjects will attend a final
Follow-Up Visit 6 weeks after the end of treatment. The primary objective of this study is to
evaluate the long-term safety and tolerability of RSG XR in subjects with mild-to-moderate AD
who have completed AVA105640. The secondary objective of this study is to explore further the
long-term efficacy of RSG XR in terms of cognitive function and overall clinical response as
a function of apolipoprotein E (APOE) e4 allele status